H290 is a type of monoclonal antibody that targets the PD-1 receptor on immune cells. It is designed to enhance the immune system's ability to recognize and attack cancer cells. By blocking the interaction between PD-1 and its ligands, H290 can potentially improve the effectiveness of cancer immunotherapy. This antibody is being studied in clinical trials for various types of cancer, including lung cancer and melanoma. Researchers aim to determine its safety, optimal dosage, and overall effectiveness in combination with other treatments, such as chemotherapy or radiation therapy.